Skip to main content
. 2020 Oct 31;43(2):985–1001. doi: 10.1007/s11357-020-00287-w

Fig. 7.

Fig. 7

Plasma levels of GDF15, FGF21, and HN in ApoE4 carriers and non-carriers subjects. Circulating plasma levels of GDF15 (a), FGF21 (b), and HN (c) in healthy controls (HC), T2D patients without complications (T2DnC) and T2D patients with complications (T2DC), and Alzheimer’s disease patients (AD) divided by ApoE4 carriers and non-carriers subgroups. Data are expressed as mean ± SE